AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27923381 — intervention group
Group type: COMPARATOR
Intervention: QNLD3 (8.3 mg/kg quinine base every 8 h)
Number of subjects: 0
Study 27923381 — intervention group
Group type: COMPARATOR
Intervention: QNLD2 (12.5 mg/kg quinine base every 12 h)
Number of subjects: 0
Study 24946021 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg oral dose
Number of subjects: 16
Study 24946021 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 16
Study 23190713 — intervention group
Group type: EXPERIMENTAL
Intervention: Senofilcon A lenses
Number of subjects: 2154
Study 23190713 — intervention group
Group type: COMPARATOR
Intervention: Non-senA lenses (lotrafilcon B, omafilcon A, and balafilcon A)
Number of subjects: 2154
Study 19903183 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 766
Study 19903183 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 766
Study 19903183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 766
Study 19903183 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (both doses)
Number of subjects: 766
Study 18780882 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensorial rehabilitation (20 sessions in 4 weeks)
Number of subjects: 68
Study 18780882 — intervention group
Group type: COMPARATOR
Intervention: Conventional neurodevelopmental theory-based treatment (NDT) (20 sessions in 4 weeks)
Number of subjects: 68
Study 16029905 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pergolide treatment (up to 12 mg/day)
Number of subjects: 32
Study 11581508 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 French diagnostic catheters
Number of subjects: 405
Study 11581508 — intervention group
Group type: COMPARATOR
Intervention: 4 French diagnostic catheters
Number of subjects: 405
Study 9846598 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml cod liver oil daily
Number of subjects: 22
Study 9846598 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 ml cod liver oil
Number of subjects: 22
Study 9846598 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml cod liver oil
Number of subjects: 22
Study 9846598 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml cod liver oil
Number of subjects: 22
Study 9846598 — intervention group
Group type: COMPARATOR
Intervention: 0 ml cod liver oil (control)
Number of subjects: 22
Study 7916073 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo mother method (KMM)
Number of subjects: 275
Study 7916073 — intervention group
Group type: COMPARATOR
Intervention: Control (standard incubator care)
Number of subjects: 275
Study 2679241 — intervention group
Group type: EXPERIMENTAL
Intervention: Picotamide (3 x 300 mg tablets)
Number of subjects: 40
Study 2679241 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three identical tablets)
Number of subjects: 40
Study 52131 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa
Number of subjects: 38
Study 52131 — intervention group
Group type: COMPARATOR
Intervention: Levodopa alone
Number of subjects: 38
Study 6249875 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosage antithymocyte globulin (IV regimen)
Number of subjects: 67
Study 6249875 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dosage antithymocyte globulin (IM regimen)
Number of subjects: 67
Study 6249875 — intervention group
Group type: COMPARATOR
Intervention: No antithymocyte globulin treatment
Number of subjects: 67
Study 31498753 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined‐modality treatment (CMT) with 2× ABVD and 20‐Gy involved‐field radiotherapy
Number of subjects: 1150
Study 31498753 — intervention group
Group type: COMPARATOR
Intervention: ABVD alone
Number of subjects: 1150
Study 31498753 — intervention group
Group type: EXPERIMENTAL
Intervention: CMT among PET‐2-negative patients
Number of subjects: 1150
Study 31498753 — intervention group
Group type: EXPERIMENTAL
Intervention: CMT among PET‐2-positive patients
Number of subjects: 1150
Study 31498753 — intervention group
Group type: EXPERIMENTAL
Intervention: CMT with Deauville score 4 cutoff for PET-2 positivity
Number of subjects: 1150
Study 31498753 — intervention group
Group type: EXPERIMENTAL
Intervention: CMT
Number of subjects: 1150
Study 31498753 — intervention group
Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 1150
Study 28289111 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotic (flucloxacillin) and topical placebo
Number of subjects: 113
Study 28289111 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antibiotic (fusidic acid) and oral placebo
Number of subjects: 113
Study 28289111 — intervention group
Group type: COMPARATOR
Intervention: Control (oral and topical placebos)
Number of subjects: 113
Study 27264092 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 IU of vitamin D3 every day (TD3)
Number of subjects: 0
Study 27264092 — intervention group
Group type: COMPARATOR
Intervention: Placebo (TP)
Number of subjects: 0
Study 24361998 — intervention group
Group type: COMPARATOR
Intervention: Spongious allograft chips alone (Group I)
Number of subjects: 80
Study 24361998 — intervention group
Group type: EXPERIMENTAL
Intervention: Spongious allograft chips mixed with bone marrow concentrate (Group II)
Number of subjects: 80
Study 24361998 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography scans at 24 months
Number of subjects: 80
Study 23618052 — intervention group
Group type: EXPERIMENTAL
Intervention: At Home/Chez Soi (Housing First) model
Number of subjects: 0
Study 23618052 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed methods approach
Number of subjects: 0
Study 23618052 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation data
Number of subjects: 0
Study 19941668 — intervention group
Group type: EXPERIMENTAL
Intervention: High-traders (n=31)
Number of subjects: 244
Study 19941668 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-traders (n=116)
Number of subjects: 244
Study 19941668 — intervention group
Group type: EXPERIMENTAL
Intervention: No-traders (n=97)
Number of subjects: 244
Study 19941668 — intervention group
Group type: COMPARATOR
Intervention: Clusters comparison
Number of subjects: 244
Study 18158082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin (E/S)
Number of subjects: 1397
Study 18158082 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe
Number of subjects: 1397
Study 18158082 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 1397
Study 15347293 — intervention group
Group type: EXPERIMENTAL
Intervention: Papilla Base Incision (PBI)
Number of subjects: 12
Study 15347293 — intervention group
Group type: COMPARATOR
Intervention: Complete mobilization of the papilla
Number of subjects: 12
Study 12355939 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative oral administration of 5-FU followed by venous injection of MMC
Number of subjects: 0
Study 12355939 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 9594473 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-cured resin composite
Number of subjects: 50
Study 9594473 — intervention group
Group type: COMPARATOR
Intervention: Glass ionomer cement (GIC)
Number of subjects: 50
Study 8021763 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin, 15 mg/kg in two divided doses (n = 90)
Number of subjects: 180
Study 8021763 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate, 40 mg/kg in three divided doses (n = 90)
Number of subjects: 180
Study 8021763 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (n = 80)
Number of subjects: 180
Study 8021763 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate (n = 82)
Number of subjects: 180
Study 8021763 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 180
Study 8021763 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate
Number of subjects: 180
Study 2736023 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Makeup Equipment (PME) installed on MODUs
Number of subjects: 30
Study 2736023 — intervention group
Group type: COMPARATOR
Intervention: Control group (MODUs not equipped with PME)
Number of subjects: 30
Study 31299461 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment (CBT)
Number of subjects: 51
Study 31299461 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control (WLC)
Number of subjects: 51
Study 31299461 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Treatment (CBT) and Wait-list Control (WLC)
Number of subjects: 51
Study 28861199 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 123
Study 28861199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 25786408 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride for 4 weeks followed by a 6-week double-blind RCT comparing continuation of amisulpride
Number of subjects: 500
Study 25786408 — intervention group
Group type: COMPARATOR
Intervention: Switching to olanzapine after 4 weeks of amisulpride
Number of subjects: 500
Study 25786408 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine treatment in nonremitters after switching
Number of subjects: 500
Study 25786408 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial interventions to enhance adherence in a subsequent 1-year RCT
Number of subjects: 500
Study 23411538 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve catheter inserted 5 cm
Number of subjects: 70
Study 23411538 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve catheter inserted 10 cm
Number of subjects: 70
Study 23411538 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve catheter inserted 20 cm
Number of subjects: 70
Study 21999905 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment Adherence Therapy (TAT)
Number of subjects: 98
Study 21999905 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 98
Study 19552746 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg alone
Number of subjects: 12
Study 19552746 — intervention group
Group type: EXPERIMENTAL
Intervention: Anacetrapib 150 mg co-administered with simvastatin 40 mg
Number of subjects: 12
Study 16139447 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone (NET) 1mg
Number of subjects: 25
Study 16139447 — intervention group
Group type: COMPARATOR
Intervention: Dydrogesterone (DGT) 10mg
Number of subjects: 25
Study 15123023 — intervention group
Group type: EXPERIMENTAL
Intervention: Active GSR biofeedback training (n = 10)
Number of subjects: 18
Study 15123023 — intervention group
Group type: COMPARATOR
Intervention: Sham control biofeedback (n = 8)
Number of subjects: 18
Study 15123023 — intervention group
Group type: EXPERIMENTAL
Intervention: Between-group comparison
Number of subjects: 18
Study 15123023 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with biofeedback performance
Number of subjects: 18
Study 11304904 — intervention group
Group type: EXPERIMENTAL
Intervention: warfarin and bucolome (300 mg once a day)
Number of subjects: 55
Study 11304904 — intervention group
Group type: COMPARATOR
Intervention: warfarin alone
Number of subjects: 55
Study 9715781 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol-17beta (E2)
Number of subjects: 30
Study 9715781 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 30
Study 7845815 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-eluting active fixation lead
Number of subjects: 24
Study 2599657 — intervention group
Group type: EXPERIMENTAL
Intervention: Laterally condensed gutta‐percha
Number of subjects: 120
Study 2599657 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoplasticized gutta‐percha with sealer
Number of subjects: 120
Study 2599657 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoplasticized gutta‐percha without sealer
Number of subjects: 120
Study 1092617 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70 (Macrodex) - 500 ml at operation and 500 ml on the first postoperative day
Number of subjects: 0
Study 1092617 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 1092617 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70 (Macrodex)
Number of subjects: 0
Study 31107929 — intervention group
Group type: EXPERIMENTAL
Intervention: Split bone technique with autologous bone blocks
Number of subjects: 164
Study 31107929 — intervention group
Group type: COMPARATOR
Intervention: Control group (implants inserted without any augmentation procedures)
Number of subjects: 164
Study 28126706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 30
Study 28126706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28126706 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Sertraline and Placebo)
Number of subjects: 30
Study 26900251 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimodal stimulation (CI + contralateral hearing aid)
Number of subjects: 39
Study 26900251 — intervention group
Group type: COMPARATOR
Intervention: Unilateral CI (CI only)
Number of subjects: 39
Study 23608801 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified group (paralleled clipping of rectal ligament, 48 patients)
Number of subjects: 92
Study 23608801 — intervention group
Group type: COMPARATOR
Intervention: Traditional group (44 patients)
Number of subjects: 92
Study 20599325 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-rTMS
Number of subjects: 24
Study 20599325 — intervention group
Group type: COMPARATOR
Intervention: Sham-controlled HF-rTMS
Number of subjects: 24
Study 19384216 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR‐rFVIIa (4 x 400 microg/kg)
Number of subjects: 214
Study 19384216 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR‐rFVIIa (various doses)
Number of subjects: 214
Study 19384216 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR‐rFVIIa
Number of subjects: 214
Study 19384216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 17479208 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Mg citrate 300 mg/day (group A)
Number of subjects: 133
Study 17479208 — intervention group
Group type: COMPARATOR
Intervention: Untreated HF patients (group B)
Number of subjects: 133
Study 16020987 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice therapy techniques
Number of subjects: 37
Study 11743835 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 573
Study 11743835 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 573
Study 11743835 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 573
Study 9288699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 847
Study 9288699 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) 0.625 mg daily
Number of subjects: 847
Study 9288699 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 daily plus medroxyprogesterone acetate (MPA) 10 mg, days 1-12
Number of subjects: 847
Study 9288699 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 daily plus MPA 2.5 mg daily
Number of subjects: 847
Study 9288699 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 daily plus micronized progesterone (MP) 200 mg, days 1-12
Number of subjects: 847
Study 8323357 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal CPAP
Number of subjects: 120
Study 8323357 — intervention group
Group type: COMPARATOR
Intervention: Headbox oxygen
Number of subjects: 120
Study 2852252 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril, 20 to 80 mg once daily
Number of subjects: 45
Study 2852252 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine retard, 20 to 40 mg twice daily
Number of subjects: 45
Study 29076387 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint interferential current (IFC) stimulation, 14 sessions over 2 weeks
Number of subjects: 198
Study 29076387 — intervention group
Group type: COMPARATOR
Intervention: Lactulose orally (control group)
Number of subjects: 198
Study 29076387 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint interferential current (IFC) stimulation
Number of subjects: 198
Study 27344641 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised moderate-to-high intensity aerobic exercise 1 hour × 3/week for 16 weeks
Number of subjects: 200
Study 23305358 — intervention group
Group type: EXPERIMENTAL
Intervention: Locator (LA) attachment system
Number of subjects: 24
Study 23305358 — intervention group
Group type: EXPERIMENTAL
Intervention: Retentive Anchor (RA) attachment system
Number of subjects: 24
Study 22361115 — intervention group
Group type: EXPERIMENTAL
Intervention: Own first-name (OWN)
Number of subjects: 36
Study 22361115 — intervention group
Group type: COMPARATOR
Intervention: Unfamiliar first-name (OTHER)
Number of subjects: 36
Study 20110630 — intervention group
Group type: EXPERIMENTAL
Intervention: HP802-247 (allogeneic tissue engineering product)
Number of subjects: 0
Study 20110630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18344432 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of blood‐derived circulating progenitor cells (CPCs) (69 +/- 14 x 10(6) CPCs)
Number of subjects: 26
Study 18344432 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cell‐free serum)
Number of subjects: 26
Study 15800267 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen application (daily application)
Number of subjects: 0
Study 12055818 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (PZQ) chemotherapy
Number of subjects: 112
Study 10470632 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 MAC Xe with 0.6 MAC sevoflurane
Number of subjects: 35
Study 10470632 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MAC Xe with 0.3 MAC sevoflurane
Number of subjects: 35
Study 10470632 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3 MAC isoflurane
Number of subjects: 35
Study 10470632 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3 MAC sevoflurane
Number of subjects: 35
Study 10470632 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 MAC nitrous oxide (N2O) with 0.6 MAC sevoflurane
Number of subjects: 35
Study 8726951 — intervention group
Group type: EXPERIMENTAL
Intervention: mini‐Wright peak flow meter added in series with pneumotachograph
Number of subjects: 112
Study 8726951 — intervention group
Group type: COMPARATOR
Intervention: pneumotachograph alone
Number of subjects: 112
Study 1527739 — intervention group
Group type: EXPERIMENTAL
Intervention: Castable ceramic crowns
Number of subjects: 0
Study 1527739 — intervention group
Group type: COMPARATOR
Intervention: Gold crowns
Number of subjects: 0
Study 1527739 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined absolute marginal discrepancy (fit)
Number of subjects: 0
Study 1527739 — intervention group
Group type: EXPERIMENTAL
Intervention: Variance of combined absolute marginal discrepancy (fit)
Number of subjects: 0
Study 1527739 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard deviation of crowns
Number of subjects: 0
Study 1527739 — intervention group
Group type: COMPARATOR
Intervention: Individual gold crown specimens
Number of subjects: 0
Study 1527739 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual ceramic crown specimens
Number of subjects: 0
Study 6360300 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 rad in 10 daily fractions
Number of subjects: 824
Study 6360300 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 rad as a single fraction
Number of subjects: 824
Study 6360300 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 824
Study 6360300 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 824
Study 31169562 — intervention group
Group type: EXPERIMENTAL
Intervention: VITOM
Number of subjects: 92
Study 31169562 — intervention group
Group type: COMPARATOR
Intervention: no VITOM
Number of subjects: 92
Study 30833068 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus TDF (300 mg once daily)
Number of subjects: 120
Study 30833068 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa-2a plus placebo
Number of subjects: 120
Study 29024612 — intervention group
Group type: EXPERIMENTAL
Intervention: Asynchronous telepsychiatry (ATP)
Number of subjects: 158
Study 29024612 — intervention group
Group type: COMPARATOR
Intervention: Synchronous telepsychiatry (STP)
Number of subjects: 158
Study 26777408 — intervention group
Group type: EXPERIMENTAL
Intervention: CuPiD system (smartphone application with positive and corrective feedback on gait)
Number of subjects: 40
Study 26777408 — intervention group
Group type: COMPARATOR
Intervention: Active control (personalized gait advice)
Number of subjects: 40
Study 26777408 — intervention group
Group type: COMPARATOR
Intervention: Both groups (CuPiD and control)
Number of subjects: 40
Study 24246818 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise as an adjunct smoking cessation treatment
Number of subjects: 0
Study 24246818 — intervention group
Group type: COMPARATOR
Intervention: Wellness contact control program
Number of subjects: 0
Study 22081114 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal ultrasound imaging for thoracic epidural block (T5‐T6 or T6‐T7)
Number of subjects: 10
Study 22081114 — intervention group
Group type: COMPARATOR
Intervention: Usual epidural block without ultrasound (Control)
Number of subjects: 10
Study 20802206 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation ON with medication ON
Number of subjects: 13
Study 20802206 — intervention group
Group type: COMPARATOR
Intervention: Deep brain stimulation OFF with medication ON
Number of subjects: 13
Study 20802206 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation ON with medication OFF
Number of subjects: 13
Study 20802206 — intervention group
Group type: COMPARATOR
Intervention: Deep brain stimulation OFF with medication OFF
Number of subjects: 13
Study 20802206 — intervention group
Group type: COMPARATOR
Intervention: Comparison with age-matched healthy subjects
Number of subjects: 13
Study 18254794 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback with electrical pulses (Grindcare(R)), applied through EMG electrodes with a non-painful intensity (1-7 mA) during detected jaw-clenching activity.
Number of subjects: 14
Study 18254794 — intervention group
Group type: COMPARATOR
Intervention: Baseline EMG activity (no biofeedback)
Number of subjects: 14